Dongsheng Chen

PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.

Yaqin Liu, S. Deng, Qin Zhang, 2024, Carcinogenesis.

Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification

Qin Zhang, Y. Tan, Dongsheng Chen, 2023, Investigational New Drugs.

Gastrointestinal signet ring cell malignancy: current advancement and future prospects

Weiping Hong, Qingjun Hu, Qin Zhang, 2023, Investigational New Drugs.

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

H. Sha, Qing Gu, Fan Tong, 2024, Signal transduction and targeted therapy.

An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Chan Zhu, Dongsheng Chen, Xing Zhang, 2024, Frontiers in immunology.